---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-098487"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2025-10-10T23:59:59+00:00"
generated_at: "2026-05-17T04:06:44.967190+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Apogee (APGE) raises $323M, updates APG777 atopic dermatitis and asthma trials

## Summary
- Offering of 6.95M shares at $41 plus pre-funded warrants and full underwriter option exercise, net proceeds ~$323.3M.
- APG777 APEX atopic dermatitis trial enrollment increased to 320 patients; Part B enrollment expected by year-end 2025.
- Topline maintenance data from APEX Part A expected Q1 2026; 16-week induction data from Part B in Q2 2026.
- Phase 1b asthma topline data for APG777 expected in Q1 2026.

## SEC filing metadata
- accession: 0001104659-25-098487
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2025-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465925098487/0001104659-25-098487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465925098487/tm2528385d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-098487
- JSON: https://secwatch.observer/filing/0001104659-25-098487.json
- Plain text: https://secwatch.observer/filing/0001104659-25-098487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.